143 related articles for article (PubMed ID: 35209006)
21. Multi-Step In Silico Discovery of Natural Drugs against COVID-19 Targeting Main Protease.
Elkaeed EB; Youssef FS; Eissa IH; Elkady H; Alsfouk AA; Ashour ML; El Hassab MA; Abou-Seri SM; Metwaly AM
Int J Mol Sci; 2022 Jun; 23(13):. PubMed ID: 35805916
[TBL] [Abstract][Full Text] [Related]
22. In silico Studies on the Interaction between Mpro and PLpro From SARS-CoV-2 and Ebselen, its Metabolites and Derivatives.
Nogara PA; Omage FB; Bolzan GR; Delgado CP; Aschner M; Orian L; Teixeira Rocha JB
Mol Inform; 2021 Aug; 40(8):e2100028. PubMed ID: 34018687
[TBL] [Abstract][Full Text] [Related]
23. In silico Study to Evaluate the Antiviral Activity of Novel Structures against 3C-like Protease of Novel Coronavirus (COVID-19) and SARS-CoV.
Chunduru K; Sankhe R; Begum F; Sodum N; Kumar N; Kishore A; Shenoy RR; Rao CM; Saravu K
Med Chem; 2021; 17(4):380-395. PubMed ID: 32720605
[TBL] [Abstract][Full Text] [Related]
24. In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2.
Abdizadeh R; Hadizadeh F; Abdizadeh T
Mol Divers; 2022 Apr; 26(2):1053-1076. PubMed ID: 34213728
[TBL] [Abstract][Full Text] [Related]
25. Protease inhibitors targeting the main protease and papain-like protease of coronaviruses.
Capasso C; Nocentini A; Supuran CT
Expert Opin Ther Pat; 2021 Apr; 31(4):309-324. PubMed ID: 33246378
[TBL] [Abstract][Full Text] [Related]
26. Molecular docking and simulation studies of natural compounds of
Mitra D; Verma D; Mahakur B; Kamboj A; Srivastava R; Gupta S; Pandey A; Arora B; Pant K; Panneerselvam P; Ghosh A; Barik DP; Mohapatra PKD
J Biomol Struct Dyn; 2022 Aug; 40(12):5665-5686. PubMed ID: 33459176
[TBL] [Abstract][Full Text] [Related]
27. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
28. Inhibitor induced conformational changes in SARS-COV-2 papain-like protease.
Ferreira GM; Pillaiyar T; Hirata MH; Poso A; Kronenberger T
Sci Rep; 2022 Jul; 12(1):11585. PubMed ID: 35803957
[TBL] [Abstract][Full Text] [Related]
29. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
30. A Novel Ambroxol-Derived Tetrahydroquinazoline with a Potency against SARS-CoV-2 Proteins.
Krysantieva AI; Voronina JK; Safin DA
Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902093
[TBL] [Abstract][Full Text] [Related]
31. Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery.
Amin SA; Ghosh K; Singh S; Qureshi IA; Jha T; Gayen S
Mol Divers; 2022 Feb; 26(1):215-228. PubMed ID: 33675510
[TBL] [Abstract][Full Text] [Related]
32. Binding of SARS-CoV Covalent Non-Covalent Inhibitors to the SARS-CoV-2 Papain-Like Protease and Ovarian Tumor Domain Deubiquitinases.
Sivakumar D; Stein M
Biomolecules; 2021 May; 11(6):. PubMed ID: 34071582
[TBL] [Abstract][Full Text] [Related]
33. Identification of SARS-CoV-2 inhibitors targeting Mpro and PLpro using in-cell-protease assay.
Narayanan A; Narwal M; Majowicz SA; Varricchio C; Toner SA; Ballatore C; Brancale A; Murakami KS; Jose J
Commun Biol; 2022 Feb; 5(1):169. PubMed ID: 35217718
[TBL] [Abstract][Full Text] [Related]
34. In silico discovery of 3 novel quercetin derivatives against papain-like protease, spike protein, and 3C-like protease of SARS-CoV-2.
Bhattacharya K; Bordoloi R; Chanu NR; Kalita R; Sahariah BJ; Bhattacharjee A
J Genet Eng Biotechnol; 2022 Mar; 20(1):43. PubMed ID: 35262828
[TBL] [Abstract][Full Text] [Related]
35. Isolation and In Silico Inhibitory Potential against SARS-CoV-2 RNA Polymerase of the Rare Kaempferol 3-
Suleimen YM; Jose RA; Mamytbekova GK; Suleimen RN; Ishmuratova MY; Dehaen W; Alsfouk BA; Elkaeed EB; Eissa IH; Metwaly AM
Plants (Basel); 2022 Aug; 11(15):. PubMed ID: 35956550
[TBL] [Abstract][Full Text] [Related]
36. In silico prediction of potential inhibitors for the main protease of SARS-CoV-2 using molecular docking and dynamics simulation based drug-repurposing.
Kumar Y; Singh H; Patel CN
J Infect Public Health; 2020 Sep; 13(9):1210-1223. PubMed ID: 32561274
[TBL] [Abstract][Full Text] [Related]
37. High-throughput screening identifies established drugs as SARS-CoV-2 PLpro inhibitors.
Zhao Y; Du X; Duan Y; Pan X; Sun Y; You T; Han L; Jin Z; Shang W; Yu J; Guo H; Liu Q; Wu Y; Peng C; Wang J; Zhu C; Yang X; Yang K; Lei Y; Guddat LW; Xu W; Xiao G; Sun L; Zhang L; Rao Z; Yang H
Protein Cell; 2021 Nov; 12(11):877-888. PubMed ID: 33864621
[TBL] [Abstract][Full Text] [Related]
38. Computational Evidences of Phytochemical Mediated Disruption of PLpro Driven Replication of SARS-CoV-2: A Therapeutic Approach against COVID-19.
Balkrishna A; Mittal R; Arya V
Curr Pharm Biotechnol; 2021; 22(10):1350-1359. PubMed ID: 33176643
[TBL] [Abstract][Full Text] [Related]
39. Targeting SARS-CoV-2 main protease: structure based virtual screening, in silico ADMET studies and molecular dynamics simulation for identification of potential inhibitors.
Uniyal A; Mahapatra MK; Tiwari V; Sandhir R; Kumar R
J Biomol Struct Dyn; 2022 May; 40(8):3609-3625. PubMed ID: 33226303
[TBL] [Abstract][Full Text] [Related]
40. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]